SCLC-Y is characterized by WT RB1 enrichment [62] and low or absent expression of ASCL1, NEUROD1, and other neuroendocrine markers, accounting for approximately 5% to 10% of SCLC tumors. This evidence concerns the gene ASCL1 and small cell lung carcinoma.